Additional Information
| Product Name: | PF-07321332 | ||
|---|---|---|---|
| Also Known As: | PF07321332, Paxlovid, 3CL protease inhibitor | ||
| Catalog No.: | F1000-2 | ||
| Size: | 2 mg | ||
| Molecular Weight: | 499.53 g/mol | ||
| Species: | N/A | ||
| Source: | Synthetic | ||
| Stock: | Powder | ||
| Concentration: | N/A | ||
| Quality Assurance: | >99% by HPLC and NMR | ||
| Storage: | Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and light. | ||
| PDF Data Sheet: | PDF Datasheet， MSDS | ||
| NCBI RefSeq: | N/A | ||
| Image(s): | (Click image to enlarge) ,  (Click image to enlarge)
|
||
| Shipping Method: | Room temperature shipping | ||
| References: | Vandyck K, Deval J, (2021) Current Opinion in Virology. 49, 36-40. |
Details
PF-07321332 is an orally active covalent inhibitor of the 3C-like protease by direct binding of the catalytic cysteine 145. 3CL protease cleaves polyproteins 1a and 1ab of SARS-CoV-2, a step required for reproduce the virus. The PF-07321332/ritonavir combination drug (trade name Paxlovid) is efficient for the treatment of COVID-19 as, in November 2021, Pfizer announced phase 2/3 clinal trial results that the drug treatment reduced 89% in hospitalizations when given within three days after symptom onset. This product is for research use only.
